Podcasts

Podcast: From platform to patient, CGTs must be more accessible

We sit down with Ori Biotech‚Äôs CEO Jason Foster to discuss the company‚Äôs paperless platform journey to commercialization and to delve deep into the challenges associated with accessing advanced therapies. This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Jason Foster, CEO of Ori Biotech. The company experienced a year of transition in 2022 with the closing of its $100 million Series B funding round and the expansion of its paperless cell and…

Ireland’s in the (up/down) stream: NIBRT talks bioproduction

The latest edition of the BioProcess Insider Expression Platform has NIBRT‚Äôs Killian O’Driscoll speaking on Ireland‚Äôs robust biomanufacturing environment, training programs, and vendor-led technologies. Ireland has long established itself as a drug manufacturing hub and is home to commercial production sites run by Big Pharma firms including Pfizer, J&J, Eli Lilly, and AstraZeneca, as well as numerous third-party manufacturing organizations and bioprocess vendor firms. The country has evolved to mirror industry‚Äôs shift from small molecule to large molecule, and now…

Podcast: Selecting a CDMO? Know your molecule, know your timeline

With expertise in development and CMC in short supply globally, CDMO choice is absolutely critical for sponsors relying on them to accelerate development pathway, says Pharmatech Associates. Ahead of November‚Äôs CPhI Worldwide event in Frankfurt, Germany, BioProcess Insider hosted a LinkedIn Live discussion with Bikash Chatterjee and Stephanie Gaulding, the respective CEO and MD at drug development consultancy firm Pharmatech Associates about current outsourcing strategies and how to go about selecting a CDMO partner. Listen to the full discussion, as…

Podcast: Turning out talent and the trials of training in the bioprocess space

Training, virtual reality, and uptake in courses are all critical factors that need to be addressed to meet the demand for talent in the advanced therapy space, according to industry academics. This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Stuart Curbishley, head of business and project development, advanced therapies at University of Birmingham and Ivan Wall, CEO, Four-Plus and¬†director of the National Training Center for advanced therapies manufacturing. We delve deep into…

Podcast: Lumen using spirulina to make ‚Äėedible‚Äô antibody drugs

We sit down with Lumen Biosciences CEO Brian Finrow to discuss how his company hopes to use its spirulina-based platform to develop drugs targeting gastrointestinal disorders. Lumen Biosciences is a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. The firm is developing ‚Äėoral antibodies‚Äô using its platform based on spirulina‚Äď the protein-rich cyanobacteria touted by many health enthusiasts as a ‚Äėsuperfood‚Äô ‚Äď to create tiny factories…

Podcast: Cytiva cites COVID as driver for biopharma resilience

Emmanuel Ligner, CEO of self-described bioprocess “critical actor” Cytiva talks us through the changing biomanufacturing landscape and unveils his firm‚Äôs sustainability report in the latest BioProcess Insider Expression Platform podcast. In 2021, Cytiva launched a survey measuring industry‚Äôs confidence in the biopharma space. Focusing across five pillars ‚Äď supply chain resilience, talent pool, the R&D ecosystem, manufacturing agility, and government policy and regulation ‚Äď the¬†Biopharma Resilience Index¬†averaged an overall score of 6.6 out of 10 in 2021. Feedback from 2022‚Äôs…

Podcast: Fujifilm Diosynth CEO on pandemics, CAPEX, and CGT ambitions

Martin Meeson discusses Fujifilm Diosynth Biotechnologies‚Äôs role in pandemics past and future, and why the CDMO just won‚Äôt stop investing in capacity. The BioProcess Insider Expression Platform (BIEP) is back, bringing you some of the conversations you may have missed at BIO 2022 in San Diego, California. We sat down with Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, to discuss industry’s learnings from the pandemic. ‚Äú[COVID-19] was a pandemic but I just worry we forget and we won’t use the…

Podcast: Opening the gates for women in biotech

There is no lack of talented women in the biotech space but the gates blocking their progression must be open for them to fully realize their potential, says consultant Nadine Ritter. Companies‚Äô Diversity, Equality, and Inclusion (DEI) policies are too often just an exercise in box-checking, said Nadine Ritter, president and analytical advisor at Global Biotech Experts and long-time member of BioProcess International‚Äôs editorial board. ‚ÄúIf it‚Äôs just virtual signaling on a website then I don‚Äôt care‚Ķ show me the…

Podcast: Biopharma’s evolving relationships with CDMOs

M&A, new modalities, and COVID-19 have all changed the way drug sponsors work with their third-party manufacturers, according to delegates from Samsung Biologics, Catalent, and AGC Biologics. The BioProcess Insider Expression Platform (BIEP) podcast is back, with an in-depth look at the evolving relationships between biopharma and their contract development and manufacturing organization (CDMO) partners. Recorded live from EBD‚Äôs BIO Europe Spring event last month, BioProcess Insider discussed the changing dynamic and reliance drug sponsors have with their CDMOs with:…

COVID drove innovation in consumables sourcing and inventory management

COVID-19 has changed how drugs and vaccines are made according to experts who say limited raw material supplies and manufacturing capacity have forced industry to innovate in sourcing and inventory management. The pandemic has disrupted the global supply of consumables and technologies according to Josh Speidel from Latham BioPharm Group, who said on BioProcess Insider‚Äôs recent State of the Industry webinar that delivery timelines have increased significantly. ‚ÄúThe pandemic has put immense pressure on the global manufacturing capacity‚ÄĚ adding that…